Similar Articles

Browse Main Topics:

Business
Computers & Electronics
Education & Reference
Entertainment & Leisure
Family & Home
Finance & Investment
Health
Internet
Pets & Animals
Science & Technology
Society, Politics & Culture
Sports & Recreation

Similar Articles

The Motley Fool March 3, 2009 Brian Orelli	A Tale of 2 Weeks It's been a busy two weeks at Genzyme as two nasty notes from the FDA follow two approvals.
The Motley Fool November 19, 2009 Brian Orelli	This Stock Is a Train Wreck Genzyme's string of missteps has investors nervous.
The Motley Fool February 17, 2010 Brian Orelli	Execute Well or You're Out Genzyme needs to show investors that it can rebuild.
The Motley Fool November 18, 2008 Brian Orelli	Genzyme Grounded for Thanksgiving The biotech won't get a decision on Myozyme until February.
The Motley Fool February 23, 2010 Brian Orelli	Icahn Puts His Proxy Fight Where His Money Is How patient will Carl Icahn be with Genzyme's turnaround plan? That's the $270 million question -- the value of Icahn's shares, based on his holdings at the end of the year.
The Motley Fool May 14, 2010 Ryan McBride	Genzyme in "Tough Spot" With Icahn Proxy Challenge Carl Icahn is pushing for change, but Genzyme's CEO has been pushing back.
The Motley Fool February 27, 2009 Brian Orelli	Double Approvals, Accelerated Growth Genzyme gets a pair of approvals -- one from each side of the Atlantic -- for two different products.
The Motley Fool February 3, 2010 Brian Orelli	Pfizer's Hedge Pays Off FDA wants more data from Pfizer's partner, Protalix on their treatment for Gaucher disease.
The Motley Fool April 24, 2008 Brian Lawler	FDA Stings Genzyme Earnings A nasty surprise hurts the drug developer's first quarter results.
The Motley Fool December 10, 2008 Brian Orelli	A Painless Advisory Panel Meeting Genzyme might be getting a Christmas present from the Food and Drug Administration. An FDA advisory panel unanimously recommended approval for Genzyme's osteoarthritis pain drug Synvisc-One.
The Motley Fool July 26, 2010 Brian Orelli	Beleaguered Biotech for Sale by Owner. Maybe. Will Genzyme's management sell before the turnaround is complete?
The Motley Fool April 8, 2010 Brian Orelli	Is Icahn Stuck in the Station? Saving Genzyme's train wreck may be difficult.
The Motley Fool November 24, 2010 Brian Orelli	Yay! We Don't Have to Pay an 18.5% Penalty Genzyme moves one step closer to a comeback. The company announced today that it had met its deadline for moving the fill-and-finish activities for drugs sold in the U.S. out of its beleaguered Allston, Mass., plant.
The Motley Fool June 16, 2010 Ryan McBride	Genzyme Annual Meeting Remarkably Mundane, Despite Rocky Year Genzyme's annual meeting was over in about an hour, and although the company took some hard questions from a shareholder, it appears that chairman and CEO Henri Termeer and the rest of the company's directors were easily reelected to serve on the board of directors.
The Motley Fool November 10, 2009 Brian Orelli	3 Companies Looking for Gratitude Early These three small drug companies all have PDUFA dates in the next week: Cadence Pharmaceuticals... NeurogesX... Genzyme...
The Motley Fool September 23, 2010 Ryan McBride	Genzyme Boss Not Ready to Sell to Sanofi The Dutch-born CEO is known for his tight control of decisions made at Genzyme, even to a fault.
The Motley Fool August 20, 2010 Brian Orelli	This Billionaire Likes Biotech. Should You? It depends on how much you trust management.
The Motley Fool January 26, 2009 Brian Orelli	Which One of These Is Not Like the Other? Bristol-Myers and Eli Lilly run into some comparability issues.
The Motley Fool January 9, 2008 Brian Lawler	Tracking Genzyme The biopharma updates investors on what to expect for 2008.
The Motley Fool April 20, 2006 John Bluis	Investors Jump Ship at Genzyme Clearly, Genzyme continues to invest in its business for the long term. That's the type of approach that can create a steady stream of market-beating returns for investors if they're willing to trust management.
Chemistry World April 24, 2008 James Mitchell Crow	FDA takes tough line on biologic drug The US Food and Drug Administration has rejected an application from biotechnology firm Genzyme to make its already-approved, protein-based drug Myozyme in larger batches.
The Motley Fool June 16, 2011 Brian Orelli	Are Two FDA Approvals in One Week a Positive Sign? Bristol-Myers Squibb received Food and Drug Administration approval for its kidney transplant drug Nulojix yesterday, marking the second approval this week from the FDA.
The Motley Fool March 3, 2009 Brian Orelli	Stop Worrying About Follow-On Biologics They're inevitable, but they won't hurt biotech as much as you might think.
The Motley Fool June 10, 2010 Brian Orelli	Cancel the Clowns: Icahn Avoids a Circus The billionaire investor backs down from a fight. He withdrew his slate of candidates to join Genzyme's board yesterday.
The Motley Fool July 12, 2006 Brian Lawler	Genzyme Continues to Deliver The biopharmaceutical company releases their second quarter earnings announcement. The stock is up sharply today, almost 8%, after Genzyme reported earnings of $0.68 a share.
The Motley Fool February 25, 2011 Brian Orelli	Minor Delay, Major Missed Opportunity Protalix and Pfizer's Gaucher disease drug gets delayed.
The Motley Fool September 30, 2008 Brian Lawler	No Approval for You ... Yet The FDA makes Eli Lilly wait for word on a lead drug.
The Motley Fool January 5, 2010 Brian Orelli	A Deal Manufactured by Necessity Genzyme gets some help from a new friend.
The Motley Fool August 3, 2009 Brian Orelli	The Roller-Coaster Stock That Keeps on Giving Savient's gout treatment isn't approved just yet.
The Motley Fool November 18, 2010 Brian Orelli	Genzyme: Slimmed Down, Gussied Up But will anyone buy it?
The Motley Fool October 22, 2009 Brian Orelli	The Gift That Keeps on Giving Genzyme's manufacturing issues just won't go away. Four months after the company announced that it had shut down a manufacturing plant because of viral contamination, its stock is still dealing with the aftermath.
The Motley Fool September 9, 2010 Brian Orelli	Will These Drugs Get Past the FDA This Month? See what the FDA has on its decision calendar for the rest of September.
The Motley Fool October 22, 2010 Brian Orelli	No Swelling Sales Here ViroPharma saw its stellar launch of hereditary angioedema treatment Cinryze come to a standstill until it could scale up manufacturing further.
The Motley Fool March 27, 2009 Brian Orelli	Dyax: A Cinderella Story Ends in a Fall FDA asks Dyax for more information.
The Motley Fool April 5, 2010 Brian Orelli	1 Month to Go! Is Dendreon a Buy? Only if you understand the risks.
The Motley Fool November 14, 2008 Brian Orelli	Gravy or Turkey From the FDA? Johnson & Johnson, Genzyme, and AstraZeneca should be made aware of their FDA fate over the next few weeks.
The Motley Fool February 16, 2010 Brian Orelli	For Blockbuster Cancer Drugs, Approvals Are the Easy Part Don't get too excited. As an investor, you can lower your risk by investing in cancer drug companies after a clinical trial success but before an FDA approval, but you'll also reduce your reward.
The Motley Fool October 21, 2010 Brian Orelli	Genzyme: Nice Quarter, Still Too Expensive After its train wreck of manufacturing problems, Genzyme seems like it's getting the cars back on track.
The Motley Fool January 26, 2005 John Bluis	Genzyme Feels the Heat Drug company faces first true competition to its enzyme replacement therapy for Gaucher disease.
The Motley Fool November 14, 2007 Brian Lawler	Genzyme Zigs, Shares Zag Genzyme gets downbeat news that will delay the launch of its lead drug, but shares rise. Investors, take note.
The Motley Fool August 30, 2010 Brian Orelli	Shocker: Sanofi's Interested in Genzyme But there are a lot of reason for Genzyme's management to shun the bid. Will it come to fruition?
The Motley Fool December 22, 2009 Brian Orelli	2009 Biotech Cheers and Jeers Lessons from biotech's 2009 surprises. Will 2010 be just as exciting? Considering that it's biotech, I'd have to say "yes."
The Motley Fool January 29, 2010 Brian Orelli	Icahn Back to Batter Biogen The old guy has tenacity.
The Motley Fool April 11, 2008 Brian Lawler	Amgen's Unsurprising Delay The FDA extends its review of an Amgen drug candidate.
The Motley Fool October 28, 2010 Brian Orelli	This Takeover's Going Nowhere Fast The Sanofi-Genzyme Drama, Take 37.
The Motley Fool December 31, 2010 Brian Orelli	2010 FDA Approvals and a Look Ahead Recent history can help us handicap FDA decisions.
BusinessWeek March 22, 2004 Gene G. Marcial	Look Who May Be Courting Bioenvision Genzyme may be interested in Bioenvision as well. Why? In 2001, Bioenvision licensed to ILEX the right to co-develop and market in the U.S. and Canada its Clorfarabine, a drug for leukemia. Bioenvision still holds the rights outside North America. The company will soon file for Food & Drug Administration approval of Clorfarabine, which has a $1 billion market potential.
The Motley Fool October 29, 2007 Brian Lawler	Genzyme Gets It Together Genzyme may not engender as much investor excitement as Carl-Icahn-acquisition-hyped biopharmas. But its diverse pipeline, and the strong performance it delivers quarter after quarter, deserve some investor attention.
The Motley Fool December 7, 2011 Brian Orelli	As the Biotech Saying Goes... Another delay for Protalix BioTherapeutics makes you think.
The Motley Fool December 9, 2008 Brian Orelli	The FDA Can't See the Forest or the Trees Forest Laboratories and Cypress Bioscience are still waiting for FDA approval, but now they've got more data to prove their point.